Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Amy E. Colson, Princy N. Kumar, Peter Jerome Ruane, Ploenchan Chetchotisakd et autres
us, vn, th, Afrique du Sud, gb, au, ar, ch, jp, tw, nl, pl (code pays fourni par la source)
2 citations
The Lancet